New Spiro[Cycloalkane-Pyridazinone] Derivatives with Favorable Fsp3 Character
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
C9-14 Aliphatic [2-25% Aromatic] Hydrocarbon Solvents Category SIAP
CoCAM 2, 17-19 April 2012 BIAC/ICCA SIDS INITIAL ASSESSMENT PROFILE Chemical C -C Aliphatic [2-25% aromatic] Hydrocarbon Solvents Category Category 9 14 Substance Name CAS Number Stoddard solvent 8052-41-3 Chemical Names Kerosine, petroleum, hydrodesulfurized 64742-81-0 and CAS Naphtha, petroleum, hydrodesulfurized heavy 64742-82-1 Registry Solvent naphtha, petroleum, medium aliphatic 64742-88-7 Numbers Note: Substances in this category are also commonly known as mineral spirits, white spirits, or Stoddard solvent. CAS Number Chemical Description † 8052-41-3 Includes C8 to C14 branched, linear, and cyclic paraffins and aromatics (6 to 18%), <50ppmV benzene † 64742-81-0 Includes C9 to C14 branched, linear, and cyclic paraffins and aromatics (10 to Structural 25%), <100 ppmV benzene Formula † and CAS 64742-82-1 Includes C8 to C13 branched, linear, and cyclic paraffins and aromatics (15 to 25%), <100 ppmV benzene Registry † Numbers 64742-88-7 Includes C8 to C13 branched, linear, and cyclic paraffins and aromatics (14 to 20%), <50 ppmV benzene Individual category member substances are comprised of aliphatic hydrocarbon molecules whose carbon numbers range between C9 and C14; approximately 80% of the aliphatic constituents for a given substance fall within the C9-C14 carbon range and <100 ppmV benzene. In some instances, the carbon range of a test substance is more precisely defined in the test protocol. In these instances, the specific carbon range (e.g. C8-C10, C9-C10, etc.) will be specified in the SIAP. * It should be noted that other substances defined by the same CAS RNs may have boiling ranges outside the range of 143-254° C and that these substances are not covered by the category. -
Supporting Information For
Electronic Supplementary Material (ESI) for Chemical Communications This journal is © The Royal Society of Chemistry 2011 Supporting Information for: 2- Quadruple-CO3 Bridged Octanuclear Dysprosium(III) Compound Showing Single-Molecule Magnet Behaviour Experimental Section Synthetic procedures All chemicals were of reagent grade and were used without any further purification. Synthesis of pyrazine-2-carbohydrazide The pyrazine-2-carboxylic acid methyl ester was prepared by a literature procedure described elsewhere. A mixture of pyrazine-2-carboxylic acid methyl ester (1.38 g, 10 mmol) and hydrazine hydrate (85%, 15 ml) in methanol (20 ml) was refluxed overnight, at a temperature somewhat below 80°C. The resulting pale-yellow solution set aside 12 hrs. During this period, a colorless product, i.e. pyrazine-2-carbohydrazide, precipitated from the reaction mixture as a crystalline solid (yield = 0.84 g, 61%). Synthesis of (E)-N'-(2-hyborxy-3-methoxybenzylidene)pyrazine-2-carbohydrazide Pyrazine-2-carbohydrazide (2 mmol, 0.276 g) was suspended together with o-vanillin (2 mmol, 0.304 g) in methanol (20 ml), and the resulting mixture was stirred at the room temperature overnight. The pale yellow solid was collected by filtration (yield = 0.56 g, 83%). Elemental analysis (%) calcd for C13H12N4O3: C, 57.35, H, 4.44, N, 20.58: found C, 57.64, H, 4.59, N, 20.39. IR (KBr, cm-1): 3415(w), 3258(w), 1677(vs), 1610(s), 1579(m). 1530(s), 1464(s), 1363(m), 1255(vs), 1153(s), 1051(w), 1021(s), 986(w), 906(m), 938(w), 736(s), 596(m), 498(w). Synthesis of the complex 1 The solution of DyCl3⋅6H2O (56.5 mg, 0.15 mmol) and the H2L (40.5 mg, 0.15 mmol) in 15 ml CH3OH/CH2Cl2 (1:2 v/v) was stirred with triethylamine (0.4 mmol) for 6h. -
Medical Prescription Market Definitions
Horvath Health Policy Innovations in Healthcare Financing Policy PO Box 196, College Park, MD 20741 202/465-5836 [email protected] Medical Prescription (Rx) Market Definitions Drug Product Terminology Small Molecule Drugs: Drugs with an active chemical ingredient that is not live, but chemically synthesized and typically are taken orally or topically, such as capsules, tablets, powders, ointments, and sprays. Brands: Also referred to “small molecule drugs,” brand drugs require original research and development for FDA licensure (also called “FDA approval”). They are approved (or licensed) under a New Drug Application (NDA). They are patent protected for 20 years total (which usually includes years clinical research before the drug is approved, or licensed). They are still referred to as brands even after the patent has expired (which distinguishes these drugs from generics). A brand can be ‘first in class” if it is a new chemical entity or new mechanism of action. It is a “me too drug” if it is not first in class. The definition of “me too” varies – different chemical composition, different mechanism of action. The drug is quite similar but different enough to get a patent. Generic: Small molecule products that are demonstrated to be clinically equivalent to a branded product (e.g., same active ingredient and route of administration, same mechanism of action). Generics do not require original research for FDA approval. Generics come to market only after the patent has expired on the brand product. Licensed under an Abbreviated New Drug Application (ANDA) by the FDA. Large Molecule Drugs: Commonly referred to as “biologics” and “biosimilars.” They contain live active ingredients and are generally infused or injected, and otherwise not taken orally or topically. -
IND Exemptions Chart
IND EXEMPTIONS Involving Drugs or Biologics Exemption 1 Exemption 4 Drug/Biologic US product Placebo * Drug/biologic product lawfully marketed in US * The clinical investigation involves the use of a placebo and the investigation does not otherwise * The investigation is not intended to be reported to FDA require submission of an IND as a well controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug/biologic. * The investigation proposed is not intended to support a significant change in the advertising for the drug/ Exemption 5 biologic In Vivo Bioavailability or Bioequivalence * The investigation does not involve a route of * Test product does not contain a new chemical administration, dose, patient population, or other factor entity”’ as defined in 21 CFR 314.108(a) [** a drug that significantly increases the risks (or decreases the that contains no active moiety that has been acceptability of the risks) associated with the use of the approved by FDA in any other application. drug/biologic * The study does not involve a radioactively labeled * The investigation will be conducted in compliance with drug product. FDA regulations for the Protection of Human Subjects and Institutional Review Boards 21 CFR 50 & 56 * The study does not involve a cytotoxic drug product. * The investigation will be conducted in compliance with The investigator will conduct a bioavailability or the FDA requirements for Promotion and Charging for bioequivalence study -
Hydrous Hydrazine Decomposition for Hydrogen Production Using of Ir/Ceo2: Effect of Reaction Parameters on the Activity
nanomaterials Article Hydrous Hydrazine Decomposition for Hydrogen Production Using of Ir/CeO2: Effect of Reaction Parameters on the Activity Davide Motta 1, Ilaria Barlocco 2 , Silvio Bellomi 2, Alberto Villa 2,* and Nikolaos Dimitratos 3,* 1 Cardiff Catalysis Institute, School of Chemistry, Cardiff University, Cardiff CF10 3AT, UK; [email protected] 2 Dipartimento di Chimica, Università degli Studi di Milano, 20133 Milano, Italy; [email protected] (I.B.); [email protected] (S.B.) 3 Dipartimento di Chimica Industriale e dei Materiali, Alma Mater Studiorum Università di Bologna, 40136 Bologna, Italy * Correspondence: [email protected] (A.V.); [email protected] (N.D.) Abstract: In the present work, an Ir/CeO2 catalyst was prepared by the deposition–precipitation method and tested in the decomposition of hydrazine hydrate to hydrogen, which is very important in the development of hydrogen storage materials for fuel cells. The catalyst was characterised using different techniques, i.e., X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), scanning electron microscopy (SEM) equipped with X-ray detector (EDX) and inductively coupled plasma—mass spectroscopy (ICP-MS). The effect of reaction conditions on the activity and selectivity of the material was evaluated in this study, modifying parameters such as temperature, the mass of the catalyst, stirring speed and concentration of base in order to find the optimal conditions of reaction, which allow performing the test in a kinetically limited regime. Citation: Motta, D.; Barlocco, I.; Bellomi, S.; Villa, A.; Dimitratos, N. Keywords: iridium; cerium oxide; hydrous hydrazine; hydrogen production Hydrous Hydrazine Decomposition for Hydrogen Production Using of Ir/CeO2: Effect of Reaction Parameters on the Activity. -
United States District Court for the District of Columbia
Case 1:15-cv-00802-RC Document 29 Filed 03/15/16 Page 1 of 33 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA FERRING PHARMACEUTICALS, INC., : : Plaintiff, : Civil Action No.: 15-0802 (RC) : v. : Re Document Nos.: 20, 22 : SYLVIA M. BURWELL, et al., : : Defendants. : MEMORANDUM OPINION GRANTING IN PART AND DENYING IN PART DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT AND DENYING PLAINTIFF’S MOTION FOR SUMMARY JUDGMENT I. INTRODUCTION Plaintiff Ferring Pharmaceuticals, Inc. (“Ferring”) is the manufacturer of PREPOPIK, a fixed-dose combination drug product that contains three drug substances: sodium picosulfate, magnesium oxide, and anhydrous citric acid. When it submitted a New Drug Application (“NDA”) for PREPOPIK to the U.S. Food and Drug Administration (“the FDA”), Ferring sought a five-year period of marketing exclusivity because one of the drug substances, sodium picosulfate, had never previously been approved in a NDA. The Federal Food, Drug, and Cosmetics Act (“FDCA”) provides for a five-year period of marketing exclusivity when a drug application is approved “for a drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application.” 21 U.S.C. § 355(j)(5)(F)(ii). During that five-year period, “no application may be submitted . which refers to the drug for which the subsection (b) application was submitted.” Id. The dispute in this case is whether the statutory term “drug,” as used in this provision of the FDCA, can reasonably be read to refer to a “drug product” (the finished dosage form of a Case 1:15-cv-00802-RC Document 29 Filed 03/15/16 Page 2 of 33 drug), or must be read to refer to a “drug substance” (the active ingredient of the drug). -
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) October 2014 Procedural New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) October 2014 Procedural Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND ............................................................................................................... 2 III. STATUTORY AND REGULATORY FRAMEWORK ............................................... 2 IV. FDA’S HISTORICAL INTERPRETATION OF THE 5-YEAR NCE EXCLUSIVITY PROVISIONS ....................................................................................... 5 V. REVISED AGENCY INTERPRETATION OF THE 5-YEAR NCE EXCLUSIVITY PROVISIONS ................................................................................................................... -
Periodic Trends in the Main Group Elements
Chemistry of The Main Group Elements 1. Hydrogen Hydrogen is the most abundant element in the universe, but it accounts for less than 1% (by mass) in the Earth’s crust. It is the third most abundant element in the living system. There are three naturally occurring isotopes of hydrogen: hydrogen (1H) - the most abundant isotope, deuterium (2H), and tritium 3 ( H) which is radioactive. Most of hydrogen occurs as H2O, hydrocarbon, and biological compounds. Hydrogen is a colorless gas with m.p. = -259oC (14 K) and b.p. = -253oC (20 K). Hydrogen is placed in Group 1A (1), together with alkali metals, because of its single electron in the valence shell and its common oxidation state of +1. However, it is physically and chemically different from any of the alkali metals. Hydrogen reacts with reactive metals (such as those of Group 1A and 2A) to for metal hydrides, where hydrogen is the anion with a “-1” charge. Because of this hydrogen may also be placed in Group 7A (17) together with the halogens. Like other nonmetals, hydrogen has a relatively high ionization energy (I.E. = 1311 kJ/mol), and its electronegativity is 2.1 (twice as high as those of alkali metals). Reactions of Hydrogen with Reactive Metals to form Salt like Hydrides Hydrogen reacts with reactive metals to form ionic (salt like) hydrides: 2Li(s) + H2(g) 2LiH(s); Ca(s) + H2(g) CaH2(s); The hydrides are very reactive and act as a strong base. It reacts violently with water to produce hydrogen gas: NaH(s) + H2O(l) NaOH(aq) + H2(g); It is also a strong reducing agent and is used to reduce TiCl4 to titanium metal: TiCl4(l) + 4LiH(s) Ti(s) + 4LiCl(s) + 2H2(g) Reactions of Hydrogen with Nonmetals Hydrogen reacts with nonmetals to form covalent compounds such as HF, HCl, HBr, HI, H2O, H2S, NH3, CH4, and other organic and biological compounds. -
Natural Products As Leads to Potential Drugs: an Old Process Or the New Hope for Drug Discovery?
J. Med. Chem. 2008, 51, 2589–2599 2589 Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery? David J. Newman† Natural Products Branch, DeVelopmental Therapeutics Program, DCTD, National Cancer InstitutesFrederick, P.O. Box B, Frederick, Maryland 21702 ReceiVed April 5, 2007 I. Introduction From approximately the early 1980s, the “influence of natural products” upon drug discovery in all therapeutic areas apparently has been on the wane because of the advent of combinatorial chemistry technology and the “associated expectation” that these techniques would be the future source of massive numbers of novel skeletons and drug leads/new chemical entities (NCEa) where the intellectual property aspects would be very simple. As a result, natural product work in the pharmaceutical industry, except for less than a handful of large pharmaceutical compa- nies, effectively ceased from the end of the 1980s. Figure 1. Source of small molecule drugs, 1981–2006: major What has now transpired (cf. evidence shown in Newman categories, N ) 983 (in percentages). Codes are as in ref 1. Major and Cragg, 20071 and Figures 1 and 2 below showing the categories are as follows: “N”, natural product; “ND”, derived from a natural product and usually a semisynthetic modification; “S”, totally continued influence of natural products as leads to or sources synthetic drug often found by random screening/modification of an of drugs over the past 26 years (1981–2006)) is that, to date, existing agent; “S*”, made by total synthesis, but the pharmacophore there has only been one de novo combinatorial NCE approved is/was from a natural product. -
Cycloalkanes, Cycloalkenes, and Cycloalkynes
CYCLOALKANES, CYCLOALKENES, AND CYCLOALKYNES any important hydrocarbons, known as cycloalkanes, contain rings of carbon atoms linked together by single bonds. The simple cycloalkanes of formula (CH,), make up a particularly important homologous series in which the chemical properties change in a much more dramatic way with increasing n than do those of the acyclic hydrocarbons CH,(CH,),,-,H. The cyclo- alkanes with small rings (n = 3-6) are of special interest in exhibiting chemical properties intermediate between those of alkanes and alkenes. In this chapter we will show how this behavior can be explained in terms of angle strain and steric hindrance, concepts that have been introduced previously and will be used with increasing frequency as we proceed further. We also discuss the conformations of cycloalkanes, especially cyclo- hexane, in detail because of their importance to the chemistry of many kinds of naturally occurring organic compounds. Some attention also will be paid to polycyclic compounds, substances with more than one ring, and to cyclo- alkenes and cycloalkynes. 12-1 NOMENCLATURE AND PHYSICAL PROPERTIES OF CYCLOALKANES The IUPAC system for naming cycloalkanes and cycloalkenes was presented in some detail in Sections 3-2 and 3-3, and you may wish to review that ma- terial before proceeding further. Additional procedures are required for naming 446 12 Cycloalkanes, Cycloalkenes, and Cycloalkynes Table 12-1 Physical Properties of Alkanes and Cycloalkanes Density, Compounds Bp, "C Mp, "C diO,g ml-' propane cyclopropane butane cyclobutane pentane cyclopentane hexane cyclohexane heptane cycloheptane octane cyclooctane nonane cyclononane "At -40". bUnder pressure. polycyclic compounds, which have rings with common carbons, and these will be discussed later in this chapter. -
Introduction to Alkenes and Alkynes in an Alkane, All Covalent Bonds
Introduction to Alkenes and Alkynes In an alkane, all covalent bonds between carbon were σ (σ bonds are defined as bonds where the electron density is symmetric about the internuclear axis) In an alkene, however, only three σ bonds are formed from the alkene carbon -the carbon thus adopts an sp2 hybridization Ethene (common name ethylene) has a molecular formula of CH2CH2 Each carbon is sp2 hybridized with a σ bond to two hydrogens and the other carbon Hybridized orbital allows stronger bonds due to more overlap H H C C H H Structure of Ethylene In addition to the σ framework of ethylene, each carbon has an atomic p orbital not used in hybridization The two p orbitals (each with one electron) overlap to form a π bond (p bonds are not symmetric about the internuclear axis) π bonds are not as strong as σ bonds (in ethylene, the σ bond is ~90 Kcal/mol and the π bond is ~66 Kcal/mol) Thus while σ bonds are stable and very few reactions occur with C-C bonds, π bonds are much more reactive and many reactions occur with C=C π bonds Nomenclature of Alkenes August Wilhelm Hofmann’s attempt for systematic hydrocarbon nomenclature (1866) Attempted to use a systematic name by naming all possible structures with 4 carbons Quartane a alkane C4H10 Quartyl C4H9 Quartene e alkene C4H8 Quartenyl C4H7 Quartine i alkine → alkyne C4H6 Quartinyl C4H5 Quartone o C4H4 Quartonyl C4H3 Quartune u C4H2 Quartunyl C4H1 Wanted to use Quart from the Latin for 4 – this method was not embraced and BUT has remained Used English order of vowels, however, to name the groups -
1097.Full.Pdf
1521-009X/47/10/1097–1099$35.00 https://doi.org/10.1124/dmd.119.088708 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 47:1097–1099, October 2019 Copyright ª 2019 by The American Society for Pharmacology and Experimental Therapeutics Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities—Commentary Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities Brooke M. Rock and Robert S. Foti Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, California (B.M.R.) and Pharmacokinetics and Drug Metabolism, Amgen Research, Cambridge, Massachusetts (R.S.F.) Received July 10, 2019; accepted July 26, 2019 Downloaded from ABSTRACT The discovery and development of novel pharmaceutical therapies in experimental and analytical tools will become increasingly is rapidly transitioning from a small molecule–dominated focus to evident, both to increase the speed and efficiency of identifying safe a more balanced portfolio consisting of small molecules, mono- and efficacious molecules and simultaneously decreasing our de- clonal antibodies, engineered proteins (modified endogenous pro- pendence on in vivo studies in preclinical species. The research and dmd.aspetjournals.org teins, bispecific antibodies, and fusion proteins), oligonucleotides, commentary included in this special issue will provide researchers, and gene-based therapies. This commentary, and the special issue clinicians, and the patients we serve more options in the ongoing as a whole, aims to highlight